Nov 3, 2025 7:01 am EST Mind Medicine (MindMed) Inc. Announces Closing of Approximately $259 Million Public Offering, Including Full Exercise of the Underwriters’ Option to Purchase Additional Shares
Oct 29, 2025 10:14 pm EDT Mind Medicine (MindMed) Inc. Announces Pricing of $225 Million Public Offering
Sep 19, 2025 7:00 am EDT New MindMed Retrospective Study Presented at Psych Congress 2025 Reveals High Rates of Suicidal Ideation (SI) in Adults with Generalized Anxiety Disorder (GAD)
Sep 4, 2025 11:05 am EDT Journal of the American Medical Association (JAMA) Publishes Results from First-Ever Randomized, Placebo-Controlled Clinical Trial Assessing the Dose-Dependent Efficacy of MM120 (Lysergide D-Tartrate, LSD) in Generalized Anxiety Disorder (GAD)